Clinical trials in Tilburg – page 11

144 clinical trials in Tilburg, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Tilburg at a glance

144

clinical trials

Research sites1

Quick filters

144 trials in Tilburg

Open in trial search

Diffuse large B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

B-cell lymphoma+1

Not recruiting

Study on Epcoritamab, Rituximab, and Lenalidomide for Adults with Untreated Follicular Lymphoma

Registered drugNo placebo

Study on Epcoritamab, Rituximab, and Lenalidomide for Adults with Untreated Follicular Lymphoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Adenocarcinoma gastric

Not recruiting

Study on the Effectiveness of Paclitaxel, Docetaxel, and Oxaliplatin in Patients with Resectable Gastric Cancer

Registered drugNo placebo

Study on the Effectiveness of Paclitaxel, Docetaxel, and Oxaliplatin in Patients with Resectable Gastric Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Substances:Risankizumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Oesophageal squamous cell carcinoma

Not recruiting

Study on Bintrafusp Alfa with Chemoradiation for Patients with Esophageal Squamous Cell Carcinoma

InvestigationalNo placebo

Study on Bintrafusp Alfa with Chemoradiation for Patients with Esophageal Squamous Cell Carcinoma

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bintrafusp Alfa
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Psoriatic arthropathy

Not recruiting

Study to Predict Tofacitinib Effectiveness in Psoriatic Arthritis Patients Using Tofacitinib, Methotrexate, and Folic Acid

Registered drugNo placebo

Study to Predict Tofacitinib Effectiveness in Psoriatic Arthritis Patients Using Tofacitinib, Methotrexate, and Folic Acid

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Etanercept
Sponsor:Universitair Medisch Centrum Utrecht

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study of Pembrolizumab for Patients with Early Stage Non-Small Cell Lung Cancer After Surgery and Standard Therapy

Registered drug

Study of Pembrolizumab for Patients with Early Stage Non-Small Cell Lung Cancer After Surgery and Standard Therapy

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Chronic lymphocytic leukaemia

Not recruiting

Study of ibrutinib and venetoclax combination therapy for patients with relapsed or refractory chronic lymphocytic leukemia who have adequate kidney function

Registered drugNo placebo

Study of ibrutinib and venetoclax combination therapy for patients with relapsed or refractory chronic lymphocytic leukemia who have adequate kidney function

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ibrutinib
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Crohn's disease

Not recruiting

Study of RVT-3101 for Treating Moderate to Severe Crohn's Disease in Patients

InvestigationalNo placebo

Study of RVT-3101 for Treating Moderate to Severe Crohn's Disease in Patients

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:PF-06480605
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Breast cancer

Not recruiting

Study of Trastuzumab Deruxtecan for Patients with Unresectable or Metastatic HER2-low or HER2 IHC0 Breast Cancer

InvestigationalNo placebo

Study of Trastuzumab Deruxtecan for Patients with Unresectable or Metastatic HER2-low or HER2 IHC0 Breast Cancer

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Trastuzumab Deruxtecan
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Acute myocardial infarction+5

Not recruiting

Study on the Effects of Zalunfiban for Patients with ST-Elevation Myocardial Infarction (Heart Attack)

Investigational

Study on the Effects of Zalunfiban for Patients with ST-Elevation Myocardial Infarction (Heart Attack)

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Zalunfiban
Sponsor:Celecor Therapeutics Inc.

Contact Research Centre

Diffuse large B-cell lymphoma

Not recruiting

Study on Atezolizumab for Patients with High-Risk Diffuse Large B-Cell Lymphoma

Registered drugNo placebo

Study on Atezolizumab for Patients with High-Risk Diffuse Large B-Cell Lymphoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Tilburg

What the registry says about research in the country

01 Gastrointestinal Diseases

Research focusing on innovative treatments for inflammatory bowel diseases, particularly evaluating new therapies for Crohn's Disease and Ulcerative Colitis. Studies include long-term safety assessments and combination therapy approaches.

Ulcerative Colitis Treatment Studies
Crohn's Disease Management
Gastric Cancer Interventions

Advanced clinical trials examining novel therapeutic agents and their effectiveness in treating moderate to severe digestive conditions.

02 Cardiovascular Research

Comprehensive studies addressing cardiovascular disease management, including investigations into peripheral arterial disease and innovative approaches to reducing cardiovascular events.

Lipoprotein Management
Arterial Disease Treatment
Stroke Prevention Studies

Trials focusing on both preventive measures and treatment strategies for various cardiovascular conditions.

03 Oncology Studies

Innovative research in cancer treatment, including breast cancer, colorectal cancer, and advanced therapeutic approaches for various tumor types.

Breast Cancer Therapies
Colorectal Cancer Treatment
Leukemia Management

Studies evaluating targeted therapies and combination treatments for various stages of cancer.

04 Immunology and Inflammation

Research examining autoimmune conditions and inflammatory disorders, with particular focus on novel therapeutic approaches and long-term disease management.

Rheumatic Disease Studies
Immunotherapy Trials
Anti-inflammatory Treatments

Investigations into innovative treatment options for chronic inflammatory conditions.

Back to the Netherlands All countries